Results of the analysis of the 6 year data of the Department of Health (DH) MS Risk-sharing Scheme (RSS), published in the Lancet Neurology today, show that the disease modifying drugs Avonex, Betaferon, Copaxone and Rebif are cost effective and are clinically effective in reducing the progression of the disease in people with relapsing remitting multiple sclerosis (MS).
Researchers have started to recruit 440 people with secondary progressive MS across the UK for a trial that will look at drugs that may limit the progression of MS.
In the last couple of days, several of the national newspapers have reported "miraculous" results from stem cell treatments for people with MS. Headlines included "Stem cell reboot has MS patients dancing", "'Miracle' stem cell therapy reverses multiple sclerosis". But what are the facts behind these headlines?
Having multiple sclerosis unfortunately doesn't prevent people from developing other health conditions and these may have an impact on MS symptoms and treatment. An international study is trying to identify the most common conditions (comorbidities) experienced by people who have MS.
A study in Australia suggests that women infected with the common stomach bug Helicobacter pylori (H.pylori) have a lower risk of developing multiple sclerosis.
The Invisible Patients, a new report published today by the Neurological Alliance has found that people with MS in England are unknown to their local Clinical Commissioning Groups. The Neurological Alliance sent Freedom of Information requests to all CCGs, to ascertain how aware they are of neurological conditions in their patch.
The Scottish Medicines Consortium (SMC) has approved peginterferon beta-1a (Plegridy) as a treatment for relapsing remitting multiple sclerosis on the NHS in Scotland
Interim results from a five year stem cell study suggest the treatment could eventually be an effective way to manage relapsing remitting MS.
Fingolimod (Gilenya) was no better than placebo at reducing measures of progression in people with primary progressive MS according to information announced today.
Dimethyl fumarate was approved by NICE (National Institute for Health and Care Excellence) in August. Following a recommendation by NICE, the NHS in England and Wales has three months in which to prepare for prescribing the drug.